written on 23.06.2014
Tags:
,

Cubist's Trius buyout pays off with FDA nod on high-powered antibiotic Sivextro

TAGS: ,

Less than a year after Cubist scooped up Trius for $707 million in a bid to boost its presence in antibiotics, it can boast an FDA approval out of the deal. On Friday, the agency approved Sivextro, an antibacterial drug to treat a range of skin infections, including methicillin-resistant Staphylococcus aureus (MRSA).

Latest Report